Awards & Funding
2020: Winner, Paul Dudley White International Scholar Award, awarded to the highest-ranked abstract from Australia, Basic Cardiovascular Science Scientific Sessions (American Heart Association)
2019: Inaugural 40 under 40: most influential Asian-Australian Awards (Science and Medicine sector).
2018: Winner, Science Meets Business, Medicine Soapbox
2018: Winner, Best Publication Awards (Alfred Research Alliance)
2017: Winner, International Society of Heart Research Early Career Investigator Award
2016: Winner, Cardiac Society of Australia and New Zealand Ralph Reader Prize
2016: Winner, John Funder Early Career Scientist Award
2015: Winner, The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologist/British Pharmacology Society Outstanding Investigator Award
Competitive Funding: Sole CI or CIA Grants
2020-2022: Australian Government National Health and Medical Research Council Ideas Grant:
Exploiting Biased Agonists for Formyl Peptide Receptors as Pharmacotherapy for Pulmonary Hypertension
2020-2021: National Heart Foundation Vanguard Grant:
Formyl Peptide Receptor Agonists as Novel Therapy for Hypertension.
2020-2024: National Heart Foundation Future Leader Fellowship:
Therapeutic Targeting of Formyl Peptide Receptors to Treat Cardiovascular Disease.
2018: Diabetes Australia Research Program:
Discovering New Drugs to Treat Diabetes-induced Cardiovascular Complications.
2017-2018: Baker Early Career Scientist Small Grant:
Formyl Peptide Receptors (FPRs): A Novel Approach to Treat Hypertension.
2015: CASS (Contributing to Australian Scholarship and Science) Foundation:
Preventing Diabetes-induced Heart Failure with A Natural Anti-inflammatory Protein.
Competitive Funding: Other CI Grants
2019-2021: NHMRC Development Grant ($677K):
Prodrug Development of Biased N Alkylpyridazinones for the Acute Intravenous Treatment of Myocardial Ischaemia-Reperfusion Injury
2019-2020: JDRF RMS360 Leadership Program ($100K):
Regulatory T Cells and Kidney Disease Progression in Type 1 Diabetes.
2018-2019: The Inaugural Victorian Medical Acceleration Fund from Victorian Government ($97K):
Inhaled Formyl Peptide Receptor Agonists for Pulmonary Fibrosis.
2012-2015: The James and Elsie Borrowman Trust ($151,241 over 3 years).
Evaluating the Role of O-GlcNAcylation on The Pathogenesis of Abnormal Cardiac Function in Diabetes.